When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CNAT - Conatus Pharma's emricasan flunks late-stage NASH study; shares down 54% premarket
Conatus Pharmaceuticals
Nano cap Conatus Pharmaceuticals (NASDAQ:CNAT) is down 54% premarket on light volume on the heels of its release of topline results from a Phase 3 clinical trial, ENCORE-NF, evaluating emricasan in patients with nonalcoholic steatohepatitis (NASH) with fibrosis.
More news on: Conatus Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move,